# US 2013/0210742 A1 · Sustained-release formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0210742 A1
- Document ID: US20130210742A1
- Status: Published application
- Kind: A1
- Application number: 13/703,596
- Filed: 2011-06-23
- Published: 2013-08-15
- Earliest claimed: 2010-06-25
- Assignees: Takeda Pharmaceutical Company Limited
- Inventors: Tomomichi Futo; Hikaru Taira; Seitaro Mizukami; Naoyuki Murata
- Web page: https://patentgrep.com/patent/US20130210742A1

## CPC

- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 9/5089: {Processes}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 35/00: Antineoplastic agents
- C08J 3/005: {Processes for mixing polymers}
- C08L 67/04: Polyesters derived from hydroxycarboxylic acids, e.g. lactones (C08L67/06 takes precedence)
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- C08J 2367/04: Polyesters derived from hydroxy carboxylic acids, e.g. lactones (C08J2367/06 takes precedence)
- C08J 2389/00: Characterised by the use of proteins; Derivatives thereof
- C08L 89/00: Compositions of proteins; Compositions of derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08J: WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H (working, e.g. shaping, of plastics B29)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

The present invention relates to a sustained-release formulation comprising a metastin derivative and a lactic polymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof. The sustained-release formulation of the present invention slowly and stably releases compound (I) or a salt thereof over a long period of time and exerts medicinal effects of compound (I) or a salt thereof over a long period of time. Furthermore, the sustained-release formulation of the present invention, which improves patient's convenience by reducing frequency of administration, is an excellent formulation as a clinical medicine.

## Claims

### Claim 1

A sustained-release formulation comprising a compound represented by Formula:
(SEQ ID NO: 1)
Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2
or a salt thereof and a lactic acid polymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof.

### Claim 2 (depends on 1)

The sustained-release formulation according to claim 1, wherein the weight average molecular weight of the lactic acid polymer or a salt thereof is about 13,000 to about 17,000.

### Claim 3 (depends on 1)

The sustained-release formulation according to claim 1, which is a 3 to 6-month sustained-release formulation.

### Claim 4 (depends on 1)

The sustained-release formulation according to claim 1, which is a therapeutic or prophylactic agent for cancer.

### Claim 5 (depends on 1)

The sustained-release formulation according to claim 1, which is formulated for parenteral administration.

### Claim 6

A method for treating or preventing cancer comprising administering an effective amount of the sustained-release formulation according to clam 1 to a mammal.

### Claim 7 (depends on 1)

A method for producing the sustained-release formulation according to claim 1, comprising subjecting
(1) a W/O/W emulsion obtained by emulsifying a W/O emulsion composed of an internal water phase containing a compound represented by Formula:
(SEQ ID NO: 1)
Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2
or a salt thereof, and an oil phase containing the lactic acid polymer or a salt thereof, or
(2) an O/W emulsion obtained by emulsifying an oil phase composed of a compound represented by Formula:
(SEQ ID NO: 1)
Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2
or a salt thereof and the lactic acid polymer or a salt thereof; to an in-water drying method.

### Claim 8 (depends on 7)

The method according to claim 7, comprising subjecting an O/W emulsion obtained by emulsifying an oil phase containing a compound represented by Formula:
(SEQ ID NO: 1)
Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2
or a salt thereof and the lactic acid polymer or a salt thereof, to an in-water drying method.
